Environment-mediated drug resistance in bcr/abl-positive acute lymphoblastic leukemia

OncoImmunology

Volumn 1, Issue 5, 2012, Pages 618-629

  Feldhahn, Niklas ^a,d   Arutyunyan, Anna ^a   Stoddart, Sonia ^a   Zhang, Bin ^a,e   Schmidhuber, Sabine M ^a,f   Yi, Sun Ju ^a   Kim, Yong mi ^b,c   Groffen, John ^a,b,c   Heisterkamp, Nora ^a,b,c  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Bcr Abl; EMDR; Innate immunity and cancer; Ph positive ALL; Stroma; Transgenic mice

Indexed keywords

BCR ABL PROTEIN; GELATINASE B; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; NILOTINIB; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL DIVISION; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESISTANCE; DRUG TOLERANCE; ENVIRONMENT MEDIATED DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION PROFILING; INFLAMMATION; LEUKEMIA CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STROMA; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84874293790     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20249     Document Type: Article

References (71)

1. Heisterkamp N, Groffen J. BCR/ABL gene structure and BCR function. In: Carella A, Daley G, Eaves C, Goldman J, Hehlman R, Eds. Chronic myeloid leukemia: Biology and treatment 2001; 3-17.
2. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5:172-83; PMID:15719031; http://dx.doi. org/10.1038/nrc1567.
3. Ottmann OG, Pfeifer H. First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. Curr Opin Oncol 2009; 21:43-6; PMID:19561414; http://dx.doi.org/10.1097/01. cco.0000357476.43164.6b.
4. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, et al. Improved early event-free survival with imatinib in Philadelphia chromosomepositive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009; 27:5175-81; PMID:19805687; http://dx.doi.org/10.1200/ JCO.2008.21.2514.
5. Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 2005; 131:579-87; PMID:16351633; http://dx.doi.org/10.1111/j.1365-2141.2005.05773.x.
6. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354:166-78; PMID:16407512; http://dx.doi.org/10.1056/ NEJMra052603.
7. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10:125-34; PMID:19138562; http://dx.doi.org/10.1016/S1470-2045(08)70339-5.
8. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354:2542-51; PMID:16775235; http://dx.doi.org/10.1056/NEJMoa055104.
9. Jones D, Thomas D, Yin CC, O'Brien S, Cortes JE, Jabbour E, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 2008; 113:985-94; PMID:18615627; http://dx.doi.org/10.1002/ cncr.23666.
10. Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 2009; 16:232-45; PMID:19732723; http://dx.doi.org/10.1016/j. ccr.2009.07.030.
11. Meads MB, Gatenby RA, Dalton WS. Environmentmediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009; 9:665-74; PMID:19693095; http://dx.doi.org/10.1038/nrc2714.
12. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990; 344:251-3; PMID:2179728; http://dx.doi.org/10.1038/344251a0.
13. Kaur P, Feldhahn N, Zhang B, Trageser D, Müschen M, Pertz V, et al. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol Cancer 2007; 6:67; PMID:17958915; http://dx.doi. org/10.1186/1476-4598-6-67.
14. Mishra S, Pertz V, Zhang B, Kaur P, Shimada H, Groffen J, et al. Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/ threonine kinase CK2. Leukemia: 2007; 178-80; PMID:17082777; http://dx.doi.org/10.1038/ sj.leu.2404460.
15. Mishra S, Zhang B, Cunnick JM, Heisterkamp N, Groffen J. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. Cancer Res 2006; 66:5387-93; PMID:16707466; http://dx.doi. org/10.1158/0008-5472.CAN-05-3058.
16. Zhang B, Groffen J, Heisterkamp N. Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells. Leukemia 2007; 21:1189-97; http://dx.doi. org/10.1038/sj.leu.2404667.
17. Zhang B, Groffen J, Heisterkamp N. Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a. Blood 2005; 106:1355-61; PMID:15860663; http://dx.doi. org/10.1182/blood-2004-09-3655.
18. O'Hare T, Walters DK, Deininger MW, Druker BJ. AMN107: tightening the grip of imatinib. Cancer Cell 2005; 7:117-9; PMID:15710324; http://dx.doi. org/10.1016/j.ccr.2005.01.020.
19. Morgillo F, Lee HY. Lonafarnib in cancer therapy. Expert Opin Investig Drugs 2006; 15:709-19; PMID:16732721; http://dx.doi. org/10.1517/13543784.15.6.709.
20. Trageser D, Iacobucci I, Nahar R, Duy C, von Levetzow G, Klemm L, et al. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med 2009; 206:1739-53; PMID:19620627; http://dx.doi.org/10.1084/jem.20090004.
21. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation and lipid metabolism. J Clin Invest 2001; 108:785-91; PMID:11560944.
22. Lee KH, Ono M, Inui M, Yuasa T, Takai T. Stimulatory function of gp49A, a murine Ig-like receptor, in rat basophilic leukemia cells. J Immunol 2000; 165:4970-7; PMID:11046024.
23. Chang CC, Liu Z, Vlad G, Qin H, Qiao X, Mancini DM, et al. Ig-like transcript 3 regulates expression of proinflammatory cytokines and migration of activated T cells. J Immunol 2009; 182:5208-16; PMID:19380766; http://dx.doi.org/10.4049/jimmunol. 0804048.
24. Gu X, Laouar A, Wan J, Daheshia M, Lieberman J, Yokoyama WM, et al. The gp49B1 inhibitory receptor regulates the IFNgamma responses of T cells and NK cells. J Immunol 2003; 170:4095-101; PMID:12682239.
25. Katz HR. Inhibition of pathologic inflammation by leukocyte Ig-like receptor B4 and related inhibitory receptors. Immunol Rev 2007; 217:222-30; PMID:17498062; http://dx.doi.org/10.1111/j.1600-065X.2007.00522.x.
26. Pahl MV, Vaziri ND, Yuan J, Adler SG. Upregulation of monocyte/macrophage HGFIN (Gpnmb/ Osteoactivin) expression in end-stage renal disease. Clin J Am Soc Nephrol 2010; 5:56-61; PMID:19833906; http://dx.doi.org/10.2215/CJN.03390509.
27. Ripoll VM, Irvine KM, Ravasi T, Sweet MJ, Hume DA. Gpnmb is induced in macrophages by IFNgamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. J Immunol 2007; 178:6557-66; PMID:17475886.
28. Kuan CT, Wakiya K, Dowell JM, Herndon JE, 2nd, Reardon DA, Graner MW, et al. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 2006; 12:1970-82; PMID:16609006; http://dx.doi.org/10.1158/1078-0432.CCR-05-2797.
29. Arce I, Martínez-Muñoz L, Roda-Navarro P, Fernàndez- Ruiz E. The human C-type lectin CLECSF8 is a novel monocyte/macrophage endocytic receptor. Eur J Immunol 2004; 34:210-20; PMID:14971047; http:// dx.doi.org/10.1002/eji.200324230.
30. Graham LM, Brown GD. The Dectin-2 family of C-type lectins in immunity and homeostasis. Cytokine 2009; 48:148-55; PMID:19665392; http://dx.doi. org/10.1016/j.cyto.2009.07.010.
31. Porcheray F, Viaud S, Rimaniol AC, Léone C, Samah B, Dereuddre-Bosquet N, et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 2005; 142:481-9; PMID:16297160.
32. Zucchetto A, Benedetti D, Tripodo C, Bomben R, Dal Bo M, Marconi D, et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res 2009; 69:4001-9; PMID:19383907; http://dx.doi.org/10.1158/0008-5472.CAN-08-4173.
33. Terpos E, Politou M, Viniou N, Rahemtulla A. Significance of macrophage inflammatory protein- 1alpha (MIP-1alpha) in multiple myeloma. Leuk Lymphoma 2005; 46:1699-707; PMID:16263571; http://dx.doi.org/10.1080/10428190500175049.
34. Coelho AL, Schaller MA, Benjamim CF, Orlofsky AZ, Hogaboam CM, Kunkel SL. The chemokine CCL6 promotes innate immunity via immune cell activation and recruitment. J Immunol 2007; 179:5474-82; PMID:17911634.
35. Dolgachev V, Thomas M, Berlin A, Lukacs NW. Stem cell factor-mediated activation pathways promote murine eosinophil CCL6 production and survival. J Leukoc Biol 2007; 81:1111-9; PMID:17234680; http://dx.doi.org/10.1189/jlb.0906595.
36. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350:1828-37; PMID:15115829; http://dx.doi.org/10.1056/ NEJMoa032520.
37. Dean RA, Cox JH, Bellac CL, Doucet A, Starr AE, Overall CM. Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8 and -13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx. Blood 2008; 112:3455-64; PMID:18660381; http://dx.doi. org/10.1182/blood-2007-12-129080.
38. Kassim SY, Fu X, Liles WC, Shapiro SD, Parks WC, Heinecke JW. NADPH oxidase restrains the matrix metalloproteinase activity of macrophages. J Biol Chem 2005; 280:30201-5; PMID:15983040; http://dx.doi. org/10.1074/jbc.M503292200.
39. Meng QR, Gideon KM, Harbo SJ, Renne RA, Lee MK, Brys AM, et al. Gene expression profiling in lung tissues from mice exposed to cigarette smoke, lipopolysaccharide or smoke plus lipopolysaccharide by inhalation. Inhal Toxicol 2006; 18:555-68; PMID:16717027; http://dx.doi.org/10.1080/08958370600686226.
40. Hofmann HS, Hansen G, Richter G, Taege C, Simm A, Silber RE, et al. Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. Clin Cancer Res 2005; 11:1086-92; PMID:15709175.
41. Sarkar S, Nuttall RK, Liu S, Edwards DR, Yong VW. Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12. Cancer Res 2006; 66:11771-80; PMID:17178873; http://dx.doi. org/10.1158/0008-5472.CAN-05-0470.
42. Sato K, Shikano S, Xia G, Takao J, Chung JS, Cruz PD Jr, et al. Selective expression of vacuolar H+-ATPase subunit d2 by particular subsets of dendritic cells among leukocytes. Mol Immunol 2006; 43:1443-53; PMID:16144709; http://dx.doi.org/10.1016/j. molimm.2005.07.035.
43. Karlstetter M, Walczak Y, Weigelt K, Ebert S, Van den Brulle J, Schwer H, et al. The novel activated microglia/ macrophage WAP domain protein, AMWAP, acts as a counter-regulator of proinflammatory response. J Immunol 2010; 185:3379-90; PMID:20709948; http://dx.doi.org/10.4049/jimmunol.0903300.
44. Paul WE. Fundamental immunology. Philadelphia: Lippincott Williams & Wilkins 2003.
45. Rajakariar R, Hilliard M, Lawrence T, Trivedi S, Colville-Nash P, Bellingan G, et al. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci USA 2007; 104:20979-84; PMID:18077391; http://dx.doi. org/10.1073/pnas.0707394104.
46. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010; 11:155-61; PMID:20037584; http://dx.doi.org/10.1038/ni.1836.
47. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol 1996; 156:1-4; PMID:8598448.
48. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6:480-98; PMID:17541420; http:// dx.doi.org/10.1038/nrd2308.
49. Poyer F, Coquerel B, Pegahi R, Cazin L, Norris V, Vannier JP, et al. Secretion of MMP-2 and MMP-9 induced by VEGF autocrine loop correlates with clinical features in childhood acute lymphoblastic leukemia. Leuk Res 2009; 33:407-17; PMID:18829111; http:// dx.doi.org/10.1016/j.leukres.2008.08.019.
50. Pegahi R, Poyer F, Legrand E, Cazin L, Vannier JP, Lamacz M. Spontaneous and cytokine-evoked production of matrix metalloproteinases by bone marrow and peripheral blood pre-B cells in childhood acute lymphoblastic leukaemia. Eur Cytokine Netw 2005; 16:223-32; PMID:16266864.
51. Schneider P, Costa O, Legrand E, Bigot D, Lecleire S, Grassi V, et al. In vitro secretion of matrix metalloprotease 9 is a prognostic marker in childhood acute lymphoblastic leukemia. Leuk Res 2010; 34:24-31; PMID:19748669; http://dx.doi.org/10.1016/j.leukres. 2009.07.039.
52. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL and EGF receptor oncogenes. Cancer Cell 2006; 10:425-35; PMID:17097564; http://dx.doi.org/10.1016/j. ccr.2006.09.014.
53. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7; PMID:12490959; http:// dx.doi.org/10.1038/nature01322.
54. Robak P, Smolewski P, Robak T. The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies. Leuk Lymphoma 2008; 49:1452-62; PMID:18608871; http://dx.doi.org/10.1080/10428190802108854.
55. Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P, Mantovani A, et al. Cellular and molecular pathways linking inflammation and cancer. Immunobiology 2009; 214:761-77; PMID:19616341; http://dx.doi. org/10.1016/j.imbio.2009.06.014.
56. Kovalchuk AL, Kim JS, Park SS, Coleman AE, Ward JM, Morse HC, 3rd, et al. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci USA 2002; 99:1509-14; PMID:11805288; http:// dx.doi.org/10.1073/pnas.022643999.
57. Ramiro AR, Jankovic M, Callen E, Difilippantonio S, Chen HT, McBride KM, et al. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 2006; 440:105-9; PMID:16400328; http://dx.doi.org/10.1038/nature04495.
58. Nelson D, Ganss R. Tumor growth or regression: powered by inflammation. J Leukoc Biol 2006; 80:685-90; PMID:16864602; http://dx.doi.org/10.1189/ jlb.1105646.
59. Cheok MH, Yang W, Pui CH, Downing JR, Cheng C, Naeve CW, et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 2003; 34:85-90; PMID:12704389; http://dx.doi.org/10.1038/ng1151.
60. Rhein P, Scheid S, Ratei R, Hagemeier C, Seeger K, Kirschner-Schwabe R, et al. Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia. Leukemia 2007; 21:897-905.
61. Rhein P, Mitlohner R, Basso G, Gaipa G, Dworzak MN, Kirschner-Schwabe R, et al. CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia. Blood 2010; 115:3763-71; PMID:20228269; http:// dx.doi.org/10.1182/blood-2009-10-247585.
62. Prueitt RL, Boersma BJ, Howe TM, Goodman JE, Thomas DD, Ying L, et al. Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer 2007; 120:796-805; PMID:17096325; http://dx.doi. org/10.1002/ijc.22336
63. Yong HY, Koh MS, Moon A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs 2009; 18:1893-905; PMID:19852565; http://dx.doi. org/10.1517/13543780903321490.
64. Ringshausen I, Dechow T, Schneller F, Weick K, Oelsner M, Peschel C, et al. Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells. Leukemia 2004; 18:1964-70; http://dx.doi. org/10.1038/sj.leu.2403544.
65. Gaundar SS, Bradstock KF, Bendall LJ. p38MAPK inhibitors attenuate cytokine production by bone marrow stromal cells and reduce stroma-mediated proliferation of acute lymphoblastic leukemia cells. Cell Cycle 2009; 8:2975-83; PMID:19713744; http://dx.doi. org/10.4161/cc.8.18.9545.
66. Mayer IA, Verma A, Grumbach IM, Uddin S, Lekmine F, Ravandi F, et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferonalpha in BCR-ABL-expressing cells. J Biol Chem 2001; 276:28570-7; PMID:11353767; http://dx.doi. org/10.1074/jbc.M011685200.
67. Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L, et al. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem 2004; 279:25345-52; PMID:15056660; http://dx.doi.org/10.1074/jbc.M400590200.
68. Dumka D, Puri P, Carayol N, Lumby C, Balachandran H, Schuster K, et al. Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma 2009; 50:2017-29; PMID:19672773; http://dx.doi. org/10.3109/10428190903147637.
69. Fei F, Stoddart S, Muschen M, Kim YM, Groffen J, Heisterkamp N. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia 2010; 24:813-20; http://dx.doi. org/10.1038/leu.2009.302.
70. Hawkes SP, Li H, Taniguchi GT. Zymography and reverse zymography for detecting MMPs and TIMPs. Methods Mol Biol 2001; 151:399-410; PMID:11217315.
71. Behan JW, Yun JP, Proektor MP, Ehsanipour EA, Arutyunyan A, Moses AS, et al. Adipocytes impair leukemia treatment in mice. Cancer Res 2009; 69:7867-74; PMID:19773440; http://dx.doi. org/10.1158/0008-5472.CAN-09-0800.